Table 4.
Baseline characteristics in 110 CD patients treated with anti-interleukin-12/23 according to PTPN2 rs7234029 polymorphism.
| PTPN2 rs7234029 (n = 110) | |||
|---|---|---|---|
| Variable | Wild Type AA | Risk Type AG and GG | p-Value |
| n (%) | 79 (71.8) | 31 (28.2) | |
| Male, n (%) | 40 (50.6) | 16 (51.6) | 0.926 |
| Disease duration at baseline (years), mean ± SD | 18.0 ± 11.4 | 18.2 ± 11.1 | 0.826 |
| Age at diagnosis (years), mean ± SD | 28.8 ± 13.0 | 30.6 ± 14.7 | 0.519 |
| Montreal classification of CD: | |||
| Age, n (A1:A2:A3) | 8:55:16 | 5:19:7 | 0.617 |
| Phenotype, n (L1:L2:L3) | 29:7:43 | 9:4:18 | 0.635 |
| L4, n (%) | 8 (10.1) | 2 (6.5) | 0.722 |
| Behavior, n (B1:B2:B3) | 22:25:28, n = 75 | 8:6:17 | 0.208 |
| Perianal disease, n (%) | 23 (30.7), n = 75 | 15 (48.4) | 0.084 |
| First-degree relative(s) with IBD, n (%) | 11 (14.5), n = 76 | 8 (25.8) | 0.164 |
| First-degree relative(s) with colon cancer, n (%) | 7 (9.7), n = 72 | 3 (10.3), n = 29 | 1.000 |
| Active smoking, n (%) | 24 (32.9), n = 73 | 10 (34.5), n = 29 | 0.887 |
| Presence of at least one extraintestinal manifestation, n (%) | 46 (58.2) | 19 (61.3) | 0.769 |
| At least one prior IBD-related intestinal resection, n (%) | 48 (60.8) | 20 (64.5) | 0.715 |
| Prior IBD-related intestinal resections per disease year, median (IQR) | 0.043 ± 0.140 | 0.042 ± 0.090 | 0.637 |
CD: Crohn’s disease; IBD: inflammatory bowel disease; IQR: interquartile range; SD: standard deviation.